Introduction
Renal transplantation is the definitive and preferred treatment for end-stage renal disease. Transplant renal artery stenosis (TRAS) is the most common vascular complication after renal transplantation, with an estimated incidence of 1-23% (1-3). This discrepancy in reported incidence is probably the result of variations in monitoring strategies and surgical technique, differing thresholds for intervention, and varying lengths of follow-up (4) . (4, 5) . Percutaneous transluminal endovascular interventions (EVIs) have emerged as the treatments of choice for each subvariety, although direct comparisons between approaches are limited (6, 7) .
Previous studies have divided TRAS into several subtypes (TRAS-A [anastomotic], TRAS-P [postanastomotic], and TRAS-B [bend-kink])
EVIs provide a minimally invasive approach to treating TRAS, often obviating the need for surgical reintervention. Immediate technical success rates range from 90% to 100% (1, 8) , and patency rates have been reported at 60% to >90% after 1 year of follow-up (1, 4, 8, 9) . Complications from EVIs include arterial rupture, bleeding, pseudoaneurysm, arterial dissection, thromboembolic events, and stent malfunction/disruption, although these are relatively infrequent events (~5-10%) (6, 10) . Here, we present a novel intervention using an endovascular salvage technique to treat a known complication-stent disruption causing a bend-kink distortion of the stent leading to persistent TRAS.
Case Presentation and Results
Our recipient was a 53-year-old African American man with end-stage renal disease secondary to a congenital dysplastic kidney (right side), hypertension (HTN), and type 2 insulin-dependent diabetes. He had been receiving peritoneal dialysis for 4 years, and his blood pressure (BP) was 128/72 mm Hg while taking a low-dose angiotensin-converting enzyme inhibitor at the time of transplantation in May 2014. He received a right kidney deceased donor renal transplant into his left lower quadrant from a 27-year-old man (kidney donor profile index of 29%). The donor kidney had normal anatomy, the renal vein was lengthened by using a dual suture line vena cavaplasty, and an end-to-side anastomosis to the recipient external iliac artery was performed.
Our patient's operative course was uncomplicated; he began producing urine immediately, and he was discharged on postoperative day 4 without complications. His initial postoperative ultrasound (US) showed patent vessels, a peak anastomotic velocity of 197 cm/s, and a resistive index of 0.62. Although he continued to produce normal amounts of urine with stable laboratory values, his creatinine level was slow to normalize. Given his persistently elevated creatinine level, he underwent a percutaneous biopsy at 1 month posttransplantation (creatinine level of 2.38 mg/dL at the time), which showed no rejection but mild vascular disease. At 6 weeks posttransplantation, a duplex US revealed TRAS-A, with a peak anastomotic velocity of 409 cm/s that was confirmed with an angiogram that demonstrated a systolic BP gradient of 30 mm Hg. We elected to proceed to a balloon angioplastic reconstruction and stent the area of stenosis with a 5 9 15-mm Herculinx stent. The postintervention systolic BP gradient was 8 mm Hg, and the patient was started on dual antiplatelet therapy with aspirin and clopidogrel.
At 6 months posttransplantation (January 2015), our patient began developing worsening HTN (mean arterial pressure of 110 mm Hg while taking two medications), although his creatinine level remained stably elevated at around 2.2 mg/dL. An interim biopsy examination continued to show no rejection, but his US revealed a peak velocity of 657 cm/s. We therefore obtained a repeat angiogram, which showed his stent had become disrupted and was kinked/crushed at the anastomosis with a portion protruding into the external iliac artery. We tried to access the stent's lumen via a right-and left-sided groin approach. However, we were able to get a wire through only the stent's interstices and not through its true lumen (Figure 1 ). Given our patient's stable clinical course, we decided to watch him clinically and reintervene only if his HTN or renal function declined.
The decision to reintervene was made 12 months after our failed EVI as our patient had developed fourmedication HTN with increasing lower extremity edema, although his renal function remained stable with a serum creatinine level of~2 mg/dL. Given his persistently elevated anastomotic flows (550 cm/s), we decided to try an EVI one final time before proceeding to open surgical repair. We discontinued his clopidogrel for 1 week preintervention because we planned a combined transparenchymal and transfemoral approach.
Given our difficulties in the prior angiogram, we decided to initially access the renal arterial system through an upper-pole artery seen on US, which required going Figure 1 : A fluoroscopic image from our failed endovascular intervention: via a right groin approach, we were able to attain wire access only through the interstices of the stent. Curved arrow = stent; straight arrow = access only through the stent's interstices.
through the kidney's parenchyma. We did this with a 3 Fr system under US guidance, introducing the needle parallel to the US beam to provide better visualization and to avoid traversing other structures (Figures 2A and  2B ). Once in, we were able to pass a wire retrograde through the stent's true lumen and into the femoral artery ( Figures 3A and 3B ) from where it was snared and pulled out of the femoral sheath, providing through-andthrough control (Figure 4) . We could then upsize the wire from the femoral access to allow us to adequately use balloon angioplastic reconstruction on the crushed stent. However, we were not able to alter the position of the stent, and it continued to project into the iliac artery more than we would have liked. It did, however, still cross the anastomosis (Figures 5 and 6 ). Follow-up measurements revealed an SBP gradient of 12, with an anastomotic velocity of 344 cm/s. Our patient experienced no immediate complications and was discharged home. He was recently seen in clinic nearly 1 month postintervention-he is now taking three BP medications, his creatinine level has declined to 1.62 mg/dl, and his lower extremity edema has nearly resolved. We hope to continue titrating his BP medications (last BP measurement was 128/83 mm Hg) as allowed.
Discussion With Technical Methods
EVIs have proved to be an effective and safe option for treating all subtypes of TRAS (4). Complications, although infrequent, remain at~5% in most series (10) (11) (12) . Here, we present a combined percutaneous transrenal and transfemoral endovascular approach as a salvage technique to recanalize a crushed transplant renal artery stent. This use of a transparenchymal access approach through a transplanted kidney has not been previously reported, to our knowledge. combined with fluoroscopic guidance. Percutaneous access to an intrarenal artery using a micropuncture needle set is relatively easy as long as you can visualize the vessel with US. The 3 Fr inner dilator of the micropuncture set, which is smaller than standard renal biopsy needles, allows passage of a 0.018-inch wire. Potential complications, no different than those for any renal biopsy, include bleeding, parenchymal damage, and arteriovenous fistula formation. As with all biopsies, we have the option of embolizing the tract with gelfoam on removal of the dilator to further minimize bleeding risk.
A transparenchymal approach is commonly used in interventional radiology to perform many procedures involving the liver and kidney, and catheters up to 14 Fr can be placed. Intuitively, the larger the catheter used, the higher is the risk of a bleeding complication. Therefore, keeping catheter size to a 3 or 4 Fr system in this case further minimizes risk. Nevertheless, as with any renal angioplasty/stent procedure, good postprocedural monitoring is important: one must observe for blood loss or renal dysfunction. Admission for one-night observation is reasonable. As with other renal angioplasty or stent procedures, we routinely obtain a baseline duplex US on the day before discharge. Office follow-up in 1-2 weeks and another duplex US in 3 months represents our typical protocol unless clinical deterioration occurs.
The transrenal approach allowed us access to the stent's true lumen since the distal (intrarenal) end of the stent was not kinked and was evenly apposed to the vessel wall. Once across with a wire, we were able to adequately use angioplasty on the deformed stent via femoral access after snaring the guidewire. We first used a 2-mm balloon from the transrenal side, to keep the sheath size to a minimum, and then we completed the balloon angioplastic reconstruction by using a 5-mm balloon via the transfemoral access. We did not flare the ostium because there was a significant amount of stent protruding into the iliac artery. We also did not use intravascular US because the problem concerned the indwelling stent and not an underlying artery and because the stent itself was a sufficient marker and could be monitored as per its configuration by using fluoroscopic guidance alone. To prevent this stent complication from occurring, one must use precision technique in stent placement, with accurate placement and the avoidance of unintentional manipulation leading to stent dislocation.
Our transrenal approach allowed us to save our patient from a potentially difficult open surgical reoperation and appears to have alleviated much of his TRAS, at least in the short term. In conclusion, EVI remains the initial treatment of choice for TRAS. A percutaneous transrenal approach is a viable salvage technique to gain access to the transplant renal arterial system and may be an option for select patients with an accessible vessel on imaging and a renal artery that has flow (i.e. is not completely thrombosed).
